Every GLP-1 comparison, priced

Pay as little as $25, subject to a maximum savings of $100/month.

… Patients new to the Wegovy® Savings Offer or NovoCare® Pharmacy pay $199 for each month of 0.25 mg & 0.5 mg. Offer for 2 monthly fills through December 31, 2026, then $349 per month for Wegovy® 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg, and $399 per month for Wegovy® HD (semaglutide) injection 7.2 mg.

… Government-insured patients may use this program if they self pay and process outside of their insurance.

… The money spent and discounts on your prescription will not count toward your deductible or out-of-pocket requirements

Self-pay pricing varies by dose. Patients pay $149 for each month of 1.5 mg, $199 per month for 4 mg and $299 per month for 9 mg and 25 mg. One month defined as 1 bottle of 30 tablets.

… Government-insured patients may use this program if they self pay and process outside of their insurance.

Self-pay, starting at $299

… The $299 per month is for the Zepbound KwikPen or vial, not Zepbound single-dose Pen.

… Governmental beneficiaries excluded.

… Coverage can differ depending if you have Medicaid, VA, DOD, TRICARE®, or another state or federal medical/pharmaceutical benefit or assistance program.

… You will automatically receive the $449 purchase offer on your first purchase of the 7.5 mg, 10 mg, 12.5 mg, or 15 mg Zepbound single-patient-use KwikPen. To continue to be eligible for this purchase offer, you must complete your refill purchase

… within 45 days

… Regular price for a 1-month supply of Zepbound single-patient-use KwikPen is $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, $699 for 10 mg, $699 for 12.5 mg, and $699 for 15 mg.

pay as little as $25 for a 1-month, 2-month, or 3-month prescription fill of Zepbound single-dose pen.

… Card savings are subject to a maximum monthly savings of up to $100 per 1-month prescription, $200 per 2-month prescription, or $300 per 3-month prescription fill and a separate maximum annual savings of up to $1,300 per calendar year. Card may be used for a maximum of up to 13 prescription fills per calendar year.

… Card expires and savings end on 12/31/2026.

… commercial drug insurance that does not cover Zepbound single-dose pen

… to pay as low as $499 for your 1-month prescription fill of Zepbound single-dose pen.

to pay as little as $25 for a 1-month, 2-month, or 3-month prescription fill of Foundayo. Month is defined as 30 days

… Governmental beneficiaries excluded.

… You will automatically receive the $299 purchase offer on your first purchase of the 14.5 mg or 17.2 mg Foundayo dosages. To continue to be eligible for this purchase offer, you must complete your refill purchase of Foundayo within 45 days

… Separately, through December 31, 2026, the price of the 2.5 mg dosage is temporarily reduced to $149 per month and the price of the 5.5 mg dosage is temporarily reduced to $199 per month. Regular price for a 1-month supply of Foundayo dosages is $149 for 0.8 mg, $199 for 2.5 mg, $299 for 5.5 mg and 9 mg, and $349 for 14.5 mg and 17.2 mg.

The mean change in body weight from baseline to week 68 was -14.9% in the semaglutide group as compared with -2.4% with placebo

… Nausea and diarrhea were the most common adverse events with semaglutide; they were typically transient and mild-to-moderate in severity and subsided with time.

The estimated mean change in body weight from baseline to week 64 was -13.6% in the oral semaglutide group and -2.2% in the placebo group

… Gastrointestinal adverse events were more common with oral semaglutide than with placebo (74.0% vs. 42.2%). CONCLUSIONS: Oral semaglutide at a dose of 25 mg once daily resulted in a greater mean reduction in body weight than placebo in participants with overweight or obesity.

adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly for 72 weeks.

… The least-squares mean percent change in weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001).

… The most common adverse events in both treatment groups were gastrointestinal, and most were mild to moderate in severity and occurred primarily during dose escalation.

… (Funded by Eli Lilly; SURMOUNT-5 ClinicalTrials.gov number, NCT05822830.)

For adults with type 2 diabetes, along with diet and exercise, to improve blood sugar

… Only Novo Nordisk manufactures FDA-approved semaglutide medicines, like Ozempic.

Mounjaro is an injectable prescription medicine that is used: along with diet and exercise to improve blood sugar (glucose) in adults and children 10 years of age and older with type 2 diabetes mellitus. to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes mellitus who are at high risk for these events.

compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed.

… FDA received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products.

Ozempic® pill

… Self pay

… 1.5 mg $149/mo

… 4.0 mg $199/mo

… 9 mg $299/mo

… Self-pay pricing varies by dose. Eligibility and restrictions apply. One month defined as 1 bottle of 30 tablets.

Self-pay price: Starting at $499/month*

… * For self-pay. Prescription required. Terms apply. Additional taxes and fees may apply. (pricinginfo.lilly.com/mounjaro: The list price of Mounjaro is $1,112.16 per fill)